Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Does entyvio suppress the immune system?

See the DrugPatentWatch profile for entyvio

Entyvio (vedolizumab) is an immunosuppressant medication used to treat inflammatory bowel diseases like ulcerative colitis and Crohn's disease [1]. It works by blocking the movement of certain white blood cells, specifically lymphocytes, to the inflamed tissues in the gut [2]. This action reduces inflammation, thereby alleviating symptoms of these conditions [2].

How does Entyvio specifically affect the immune system?


Entyvio targets a specific protein, integrin alpha-4-beta-7 (α4β7), which is found on the surface of lymphocytes [3]. This integrin plays a role in directing immune cells to the gastrointestinal tract [3]. By binding to α4β7, Entyvio prevents these lymphocytes from entering the gut lining, thereby dampening the immune response that contributes to IBD [3]. This mechanism is considered gut-selective, meaning it primarily acts within the digestive system rather than broadly suppressing the entire immune system throughout the body [2][4].

What are the risks of taking Entyvio?


Because Entyvio affects the immune system, individuals taking the medication may be at an increased risk of infections [1]. Patients are advised to inform their doctor if they have an active infection or if they develop signs of infection, such as fever, chills, or a persistent cough [1]. There is also a potential, though rare, risk of certain types of cancers, including skin cancer and progressive multifocal leukoencephalopathy (PML), a serious brain infection [1].

Can Entyvio be used by pregnant or breastfeeding individuals?


For pregnant individuals, Entyvio has been evaluated, and data suggests it may be safe to use during pregnancy [5]. However, it is crucial for pregnant individuals to discuss the risks and benefits with their healthcare provider [5]. Regarding breastfeeding, Entyvio has been detected in human milk, but it is generally considered unlikely to cause harm to a nursing infant [6]. Nevertheless, consultation with a healthcare professional is recommended before breastfeeding while on this medication [6].

What is the outlook for Entyvio patents?


The patent landscape for Entyvio is dynamic. Information regarding patent expirations and exclusivities can be found on resources like DrugPatentWatch.com [7]. Analyzing these patents is crucial for understanding when generic versions of the drug might become available.



Other Questions About Entyvio :

entyvio approval date entyvio patent expiry date entyvio lawsuit entyvio pen cost entyvio long term side effects Entyvio patent expiry? Is entyvio better than humira for crohn's disease?